Phillip J. Gray

TL;DR: AT for MIBC appears underused, especially in the elderly and in groups with poor socioeconomic status, and data point to a significant unmet need to inform policy makers, payers, and physicians regarding appropriate therapies forMIBC.

TL;DR: Postoperative RT use for localized PCa in patients with adverse pathologic features is declining in the United States, and patients treated at community cancer programs, those with locally advanced disease and positive margins, and those with a high Gleason score were more likely to receive postoperative radiotherapy.

TL;DR: While use of observation is increasing in low-risk groups, the use of RP is increasing across all risk groups with a concomitant decline in use of radiotherapy.

TL;DR: Using a large national database, a statistically significant survival benefit is identified for patients with cN+ PCa treated with ADT+RT, suggesting that a substantial proportion of such patients at high risk for prostate cancer death may be undertreated, warranting a reevaluation of current practice guidelines.

TL;DR: Recent studies have suggested differing toxicity patterns for patients with prostate cancer who receive treatment with 3‐dimensional conformal radiotherapy, intensity‐modulated radiotherapy (IMRT), or proton beam therapy (PBT).